Clinical Trial Search

Primary: Mean Change in Weekly Global Gastrointestinal Symptoms Average Index Score (WGGSAIS). — -0.424; -0.185 score — p==0.1279

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours

Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL

Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003

Primary: Overall Responder 9/12 Weeks — 18.6; 16.8; 19.0; 10.7 % of Overall Responder 9/12 weeks

Primary: Time Reduction (Hours and Minutes) of Gastric Emptying (GE), Small Bowel (SB), Large Bowel (LB) and Whole Gut (WG) Transits Measured by SmartPill in Chronically…

Primary: The Number of High-Amplitude Propagating Contractions (HAPC) — 8.7; 2.9 Number of HAPC with amplitude ≥100mmHg — p=0.012

Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes

Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day

Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours

Primary: Prevalence of CSID Genetic Variants — 27; 0 Participants

Primary: A Change in Length of Spread of Antegrade Contractions After Placebo.

Primary: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) — 123; 620 Participants

Primary: The Number of Participants at Baseline With SIBO — 14; 44; 24 Participants

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.1; 4.4 SBMs/week — p=0.007

Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.6; 5.0 SBMs/week — p=0.003

Primary: Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 241; 14 Patients

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 of Administration — 6.7; 5.2 number of SBM per week — p=0.020

Primary: Percentage of 12-Week CSBM Overall Responders — 4.7; 13.4; 95.3; 86.6 percentage of participants — p=< 0.0001

Primary: Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. — 0.01; 0.02 Ratio — p=0.87

Primary: Colonic Compliance — 18.96; 16.86; 15.99; 15.75 mm Hg

Primary: Compare Changes in Number of Interventions Used to Complete Bowel Routine, Including Electrical Rectal Stimulation (Treatment) Versus Mechanical Rectal Distension…

Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…

Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour

Primary: Change in Methane Production — 10645; 14635 parts per million*minutes

Primary: Number of Durable Overall CSBM Responders, Mean Replacement Approach — 57; 88; 88 Participants

Primary: Colonic Transit, Colonic Geometric Center at 24 Hours — 2.39; 2.37; 2.02; 1.76 units on a scale

Primary: Low Back Pain After 6 Weeks of Intervention — 6.50; 6.00; 1.50; 3.50 units on a scale